GB Sciences Inducts Scientific Advisory Board: Dr. Andrea Small-Howard of GB Sciences, Dr. Helen Turner of Chaminade University, Dr. Norbert Kaminsky of Michigan State University, and Dr. Carlos Ríos-Bedoya of McLaren Health

The Scientific Advisory Board will be chaired by Dr. Andrea Small Howard, Chief Science Officer of GB Sciences, Inc. "We are very honored to welcome some new members to our Scientific Advisory Board this year; as well as, Dr. Helen Turner, who has worked with GB Sciences for the past four years. Dr. Turner, VP of Innovation, Dean of Natural Sciences and Mathematics at Chaminade University, has been my collaborator on the discovery of our novel cannabis-based therapies since the beginning, and she is a co-inventor with me on all of GB Sciences' original patent applications," said Dr. Small-Howard. "Joining the team this year are Dr. Norbert Kaminsky of Michigan State University, whose laboratory was the first to discover cannabinoid receptor expression in the immune system, who pioneered studies of the effects of cannabis on immune modulation, and who has more recently been studying the effects of cannabis use on patients with HIV/AIDS. Dr. Carlos F. Ríos-Bedoya from McLaren Health, has been a pioneer in the use of mobile technology and Patient Reported Outcome software to expedite data gathering in clinical trials. In addition, Dr. Ríos-Bedoya brings experience in clinical trial protocol development and statistics to our team." Full biographies for our Scientific Advisory Board members are available on our website.

"GB Sciences is committed to putting safe and effective cannabis-based medicines into the hands of the patients who need it, and doing it as quickly as possible," said John Poss, CEO and Chairman of GB Sciences, Inc.  "We believe that our Scientific Advisory Board has the skills and connections to make this happen."

About GB Sciences, Inc.

GB Sciences, Inc. (OTCQB: GBLX) is a diverse cannabis company, focused on standardized cultivation and production methods; as well as biopharmaceutical research and development. The Company's goal is creating safe, standardized, pharmaceutical-grade, cannabinoid therapies that target a variety of medical conditions. To learn more about GB Sciences, Inc., go to: http://gbsciences.com.

Forward-Looking Statements

This press release may contain statements relating to future results or events, which are forward-looking statements.  Words such as "expects", "intends", "plans", "may", "could", "should", "anticipates", "likely", "believes" and words of similar import may identify forward-looking statements. These statements are not historical facts, but instead represent only the Company's belief regarding future events, many of which, by their nature, are inherently uncertain and outside of the Company's control.  It is possible that the Company's actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements.  Further, information concerning the Company and its business, including factors that potentially could materially affect the Company's business and financial and other results, are contained in the Company's filings with the Securities and Exchange Commission, available at www.sec.gov.  All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.

Note:  Although the Company's research and development activities are not illegal, the production and sale of cannabis products violate federal laws as they presently exist.

Contact Information

Corporate:

GB Sciences, Inc., 3550 West Teco Ave., Las Vegas, NV 89118
866-721-0297, or 
Tom Arcuragi, SR VP Marketing, [email protected], http://gbsciences.com

SOURCE GB Sciences, Inc.

Related Links

http://gbsciences.com